Nairobi, February 22, 2026.- This week Kenya hosted its first delivery of lenacapavir, a new generation treatment for HIV prevention. This medicine, developed by the American firm Gilead Sciences, is presented as a major step forward in the fight against the transmission of the virus.
Lenacapavir is distinguished by its efficacy and method of administration, providing prolonged protection against infection. The health authorities hope that it will contribute to a significant reduction in the number of new infections, especially among pregnant and lactating women, considered to be particularly vulnerable in some regions.
This initiative has international support. The United States, in collaboration with the Global Fund to Fight AIDS, Tuberculosis and Malaria, has committed to co-finance the acquisition of treatment. The aim is to allow the distribution of lenacapavir to nearly two million people worldwide.
The arrival of this drug in Kenya is thus an important step in global efforts to curb the spread of HIV and increase access to innovative prevention tools, particularly in countries most affected by the epidemic.
W.E.
